報價延遲最少15分鐘:2025/08/25 06:09 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.05
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.69/--
|
|
企業價值
739.94M
|
| 資產負債 |
|
每股賬面淨值
6.94
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
65.12M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/25 06:09 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale ofthe iLet. |
